BioStem Technologies Financials - Benzinga

BioStem Technologies Inc

BSEMNASDAQ

Trade with Public

Trade with Public

$4.31

0.133.23%

At close: Sep 11, 5:00 PM EST

$4.30

-0.01-0.23%

After Hours: 8:28 AM EST

Overview News Earnings Forecast EventsFinancialsSentiment Compare Stock Report

BioStem Technologies Financials

BioStem Technologies (BSEM) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
BioStem Technologies Q2 EPS $(0.52), Sales $7.899M Down From $10.963M YoY

BioStem Technologies (NASDAQ:BSEM) reported quarterly losses of $(0.52) per share. The company reported $7.899 million in sales this quarter. This is a 27.95 percent decrease over sales of $10.963 million the same

Benzinga Newsdesk

EXCLUSIVE: BioStem Technologies Reports Q1 Net Revenue Up 211% YoY

BioStem Technologies Inc. (OTC: BSEM), a regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics today, reported financial results for the quarter ended March 31, 2022.

Michael Cohen